Ocular Therapeutix Inc. (OCUL)
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 7.24 +0.19%
OCUL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.59B
- EPS (TTM)
- -$1.40
- Dividend yield
- None
- 52-week range
- 6.23 – 16.44
- Day range
- 7.19 – 7.55
- Volume / Avg
- 2.92M / 2.78M
- Beta
- —
- Shares outstanding
- 219.62M
- Next earnings
- Nov 3, 2026
52-week range
OCUL stock today
Ocular Therapeutix (OCUL) closed at $7.23 on Oct 7, down 1.50% (-$0.11), versus the S&P 500's 0.22% decline. Shares are 56.0% below their 52-week high of $16.44, set on Dec 8, 2025 and 16.1% above the 52-week low of $6.23, near the bottom of the past year's range. OCUL is down 40.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 37.2%.
Ocular Therapeutix has posted a net loss over the last twelve months (EPS of -$1.40), so its P/E ratio is not meaningful. Ocular Therapeutix's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Ocular Therapeutix
Company profileOcular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Pravin U. Dugel M.D.
- Headquarters
- Bedford, MA
- Employees
- 325
- IPO year
- 2014
- Website
- ocutx.com
Analyst forecast
ForecastConsensus (11 analysts)
strong_buy
Avg. price target
$27.09+274.69%
- Strong buy 4
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.36
Ocular Therapeutix peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMPSCOMPASS Pathways Plc American Depository Shares | 11.69 | +1.12% | $1.62B | vs OCUL |
| QUREuniQure N.V. | 23.14 | +0.35% | $1.61B | vs OCUL |
| ANIPANI Pharmaceuticals Inc. | 71.93 | +0.57% | $1.65B | vs OCUL |
| ETONEton Pharmaceuticals Inc. | 54.88 | +0.20% | $1.57B | vs OCUL |
| STOKStoke Therapeutics Inc. | 24.29 | -0.33% | $1.57B | vs OCUL |
| BRVEBraveheart Bio Inc. | 18.58 | -6.11% | $1.67B | vs OCUL |
| SEPNSepterna Inc. | 36.00 | +0.93% | $1.68B | vs OCUL |
| PAHCPhibro Animal Health Corporation Class A | 37.72 | +3.03% | $1.53B | vs OCUL |
Indexes, lists and sector
Ocular Therapeutix stock FAQ
What is Ocular Therapeutix's stock price today?
OCUL last traded at $7.23 as of Oct 7, 4:00 PM EDT, down 1.50% on the day. Prices are delayed at least 15 minutes.
When is Ocular Therapeutix's next earnings date?
Ocular Therapeutix is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.36.
Who is Ocular Therapeutix's CEO?
Dr. Pravin U. Dugel M.D. is the chief executive officer of Ocular Therapeutix Inc., which has about 325 employees.
What is the OCUL 52-week high?
The 52-week high for OCUL is $16.44 and the 52-week low is $6.23. The stock is currently 56.0% below its high.